% | $
Quotes you view appear here for quick access.

Pharmacyclics, Inc. Message Board

  • insidetrack22 insidetrack22 Mar 6, 2013 2:08 PM Flag

    PCYC pull back by Friday

    Results being prepared for ASCO shows although Ibrutinib is effective, serious diarrhea complications makes it difficult to complete therapy without medical intervention by investigators. Ibrutinib market due to its side effects may be much smaller than previously anticipated since side effects may limit its therapeutic effectiveness. A therapy that cannot be tolerated efficacy rate does not matter. You have 48 hours advance warning.
    Best of luck

    SortNewest  |  Oldest  |  Most Replied Expand all replies
257.100.00(0.00%)Apr 23 3:59 PMEDT